Building 29B Overview
Building 29B was constructed from 1993 to 1994 as additional space for the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) on the National Institutes of Health (NIH) campus. It is connected to Building 29A by pedestrian bridges at three levels and at the basement level.
The five-story, 91,000-square-foot laboratory building includes a basement and penthouse.
Each floor has two wings with offices and laboratory and support space.
The upper three floors were designed with the capacity for specialty Biosafety Level 3 (BSL-3) and/or Current Good Manufacturing Practice regulations (cGMP) facilities for the production and storage of biological products.
When the FDA CBER left the NIH campus in 2014, Building 29B underwent some renovations and has since been used as overflow space for NICHD, NIAID, and NIMHD.
Until 2014, Buildings 29, 29A, and 29B represented the only facilities, not just on the NIH campus but in the entire United States, that have functioned since their construction for the primary purpose of regulating biologics.
Building 29B, at right, showing the connection between it and Building 29A.
FDA Commissioner Dr. David Kessler, at left, with Associate Commissioner Sharon Holston at the 1992 groundbreaking ceremony for Building 29B, an AIDS research facility.
FDA History Office